BioVersys

About:

BioVersys develops novel antibacterial products to combat serious life-threatening infections caused by MDR bacteria.

Website: http://www.bioversys.com

Twitter/X: bioversys

Top Investors: European Investment Bank, Venture Kick, Innosuisse, GoBeyond, GSK

Description:

Bioversys AG is a biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Their focus is on creating therapies to combat multidrug-resistant (MDR) bacterial infections, a major global health issue. BioVersys’ proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform is designed to identify new treatments by inhibiting bacterial resistance mechanisms, thereby making antibiotics more effective.